Rituximab monotherapy in relapsed lymphocyte-predominant Hodgkin�s lymphoma

• Autores: Laura Galán, Antonio C. Sánchez, B. Cantos Sánchez de Ibargüen, Mariano Provencio Pulla
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 12, Nº. 5, 2010, págs. 384-386
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Nodular lymphocyte-predominant Hodgkin�s lymphoma (NLPHL) accounts for approximately 5% of Hodgkin�s lymphoma, presents with early-stage disease and has an indolent course. Treatment is not well established. We present a patient diagnosed with NLPHL and treated with Rituximab second-line therapy after chemotherapy.